pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

728 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1606Endpoints1258BioSpace587Fierce Biotech585BioPharma Dive474raps199onclive165fda recalls105fda medwatch
therapy area
allOncology10912Rare Disease2804Immunology2568Cardiology2302Pulmonology1918Hematology1912Vaccines1662Psychiatry & CNS1111
  • Top Breast Cancer Experts Highlight Key Abstracts Ahead of 2026 ESMO Congress in Berlin
    Leading breast oncologists are sharing the abstracts they consider most important as the European Society for Medical Oncology (ESMO) Breast Cancer Congress approaches in Berlin from May 6 to 8, 20…
    onclive · 5mo agoNeutral↗ source
  • Takeda advances gene therapy, UK cancer biotech raises $83M, and new blood test may guide Wegovy use
    A Cleveland‑based biotech announced that a previously halted gene therapy program has been revived, offering a potential new option for patients as the company pursues additional studies. Takeda r…
    Endpoints · 5mo agoNeutral↗ source
← prev
page 29 of 30
next →
95
globenewswire health73
fda press55
Ophthalmology883
Endocrinology & Metabolism699
Pain678
Nephrology676
JAK inhibitor sequencing and transplant timing in myelofibrosis discussed at 2026 conference
Dr. Andrew Kuykendall of Moffitt Cancer Center explained how doctors decide the order of JAK inhibitor therapies and when to consider allogeneic stem cell transplant for myelofibrosis patients. At…
onclive · 5mo agoNeutral↗ source
  • Study links specific dietary fats to pancreatic cancer risk, highlighting oleic acid as promoter and omega-3s as protective
    Researchers at Yale Cancer Center examined how different types of dietary fat affect pancreatic cancer development in a mouse model. Rather than focusing on total fat intake, the study compared twe…
    onclive · 5mo agoNeutral↗ source
  • Experts stress seamless coordination for relapsed multiple myeloma patients across academic and community clinics
    In a recent opinion segment, Dr. Ajay K. Nooka convened a discussion with Dr. Noopur S. Raje and Dr. Surbhi Sidana about how to best coordinate care for patients with relapsed and refractory multip…
    onclive · 5mo agoNeutral↗ source
  • Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertain
    BioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results. Bristol Myers Squibb reported $11.5 billion in revenue f…
    BioPharma Dive · 5mo agoEarningsNeutral↗ source
  • Two biotech firms raise $556 million in combined IPOs
    Seaport Therapeutics and Hemab Therapeutics launched initial public offerings on Thursday, together bringing in $556.4 million to fund further development of their drug pipelines. Hemab Therapeuti…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • FDA proposes removing obesity and diabetes drug ingredients from compounding substances list
    The U.S. Food and Drug Administration has issued a proposal to remove the active ingredients of widely used obesity and diabetes medicines from the list of substances that can be compounded. The ch…
    STAT · 5mo agoRegulatoryNeutral↗ source
  • FDA drops Casey Means as surgeon general nominee, naming Fox News radiologist Nicole Saphier instead
    FDA withdrew the nomination of Casey Means for surgeon general and appointed Nicole Saphier, a radiologist and Fox News commentator. The switch underscores the administration’s limited sway in the…
    STAT · 5mo agoRegulatoryNegative↗ source
  • FDA finds low levels of PFAS in most U.S. baby formulas, says supply remains largely safe
    The FDA recently tested 312 infant formula samples from 16 brands and released its findings. The agency detected five types of PFAS, with PFOS appearing in about half of the samples, but 95% of th…
    STAT · 5mo agoRegulatoryNeutral↗ source
  • Merck remains optimistic on Terns leukemia drug despite new data
    Merck said Thursday that it still sees a compelling outlook for Terns' leukemia drug even after updated study data suggested it may be less differentiated. The updated data came from a trial of TE…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • Avalyn Pharma raises $300M in IPO to fund inhalable lung-fibrosis drugs
    Avalyn Pharma completed a $300 million initial public offering, pricing 16.7 million shares at $18 each and exceeding its original $200 million target. The proceeds will be used to develop inhalab…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • FDA appoints Katherine Szarama as acting director of vaccines and biologics center
    The FDA announced that Katherine Szarama will serve as the acting director of the Center for Biologics Evaluation and Research (CBER), the agency's unit that oversees vaccines, gene therapies and t…
    STAT · 5mo agoNeutral↗ source
  • Alternative medicine often feels more personal than conventional care, says physician
    Dr. Hannah Kerman, a New York physician, writes that many patients turn to acupuncturists or massage therapists because they feel more attended to than during typical medical visits. She describes…
    STAT · 5mo agoNeutral↗ source
  • Boehringer’s dual-acting obesity shot survodutide meets primary goal in Phase 3, showing strong weight loss and muscle-preserving effect
    Boehringer Ingelheim announced that its dual-acting injectable obesity therapy, survodutide, achieved its primary endpoint in a Phase 3 study. Participants receiving the drug lost significantly mo…
    BioPharma Dive · 5mo agoPositive readoutPositive↗ source
  • Experts warn brain-health initiatives overlook mental illness
    The authors – a professor at Oxford and Yale, the dean of Mount Sinai’s medical school, and a former U.S. congressman – argue that the surge in funding for neuroscience is being directed mainly tow…
    STAT · 6mo agoNegative↗ source
  • New hepatitis B vaccine guidance prompts analysis of public trust and policy impacts
    The Morning Rounds newsletter examines how the latest recommendations for a hepatitis B vaccine could affect public health outcomes. It highlights recent surveys that show varying levels of confid…
    STAT · 5mo agoNeutral↗ source
  • EPA proposes first rule to flag microplastics and pharmaceuticals in drinking water, alongside $144 million ARPA-H study program
    The Environmental Protection Agency announced a proposed rule that would formally label microplastics and pharmaceutical residues in drinking water as contaminants that merit federal study and trac…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Veradermics reports positive Phase 3 results for oral baldness pill
    Veradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo. The dru…
    BioPharma Dive · 6mo agoPositive readoutPositive↗ source
  • Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitor
    Eli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trial
    Oruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…
    STAT · 6mo agoPositive readoutPositive↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Lilly shares slide as Foundayo prescriptions lag expectations, while Novo's Wegovy gains momentum
    Eli Lilly's stock fell nearly 5% after the latest weekly prescription count for its obesity drug Foundayo missed analysts' expectations. IQVIA data showed U.S. prescriptions for Foundayo reached 3…
    BioPharma Dive · 6mo agoNegative readoutNegative↗ source
  • International childhood vaccine campaign expands, newsletter reports
    The latest Morning Rounds newsletter notes that a global campaign to increase childhood vaccination rates is gaining momentum. The piece highlights the growing reach of the effort without providing…
    STAT · 6mo agoNeutral↗ source
  • Novo Nordisk's GLP-1 pill shows blood-sugar reduction in teens with type 2 diabetes
    Novo Nordisk reported results from a study evaluating its oral GLP-1 therapy, Rybelsus, in adolescents with type 2 diabetes. The trial enrolled participants aged 10-17 who took the pill for roughl…
    Endpoints · 6mo agoPositive readoutPositive↗ source